To identify such preclinical studies, our search terms included mouse models with a MAPT knock‐in or transgene, many of which also had one or more MAPT mutations leading to tau pathology; mouse models such as the 3xTg mice, which also have mutations that promote amyloid pathology, were excluded.44 This evidence concerns the gene MAPT and amyloidosis.